Wednesday, February 15, 2017
15 This criticism has largely been levelled at the inclusion of activated protein C (Xigris®; Eli Lilly and Co.) in the second of the two Care Bundles (the Management Bundle). This recommendation was downgraded to Level 2 in the 2008 revisions. More scientifically solid criticism has arisen surrounding a number of other recommendations, including that for early goal-directed therapy (EGDT), discussed below.P < 0.001, for each]. These results, although limited by voluntary contribution of data, demonstrated that the use of a multifaceted improvement initiative was successful in changing sepsis treatment behaviour as demonstrated by a significant increase in compliance with performance measures. However, the SSC has not been universally acclaimed, and was fiercely criticized by some, due to its links with industry during the second phase.